Chemotherapy Induced Nausea and Vomiting Clinical Trial
Official title:
An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 13 to 17 Years)
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06065722 -
Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy
|
Phase 2 | |
Completed |
NCT01362530 -
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
|
Phase 3 | |
Recruiting |
NCT02205164 -
Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients
|
Phase 2 | |
Not yet recruiting |
NCT04873284 -
Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients
|
N/A | |
Completed |
NCT00642512 -
Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
|
Phase 3 | |
Recruiting |
NCT02097823 -
Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy
|
Phase 2 | |
Completed |
NCT01402024 -
Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy
|
Phase 3 | |
Completed |
NCT00211601 -
Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)
|
N/A | |
Completed |
NCT05792228 -
A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting
|
N/A | |
Withdrawn |
NCT01596413 -
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
|
Phase 1 | |
Withdrawn |
NCT01596426 -
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
|
Phase 1 |